

See how treatment with AMVUTTRA led to a reduction in serum TTR protein.
MOA
AMVUTTRA is an RNAi therapeutic that reduces TTR protein production1
What is AMVUTTRA?
AMVUTTRA is an RNAi therapeutic indicated for the treatment of the polyneuropathy of hATTR amyloidosis in adults.1 AMVUTTRA is a double-stranded small interfering RNA (siRNA) that is formulated for targeted delivery to hepatocytes, the primary source of TTR protein production.1-3
Choose below to see:
TTR protein in a patient with hATTR amyloidosis2,3
forms amyloid deposits
in tissues
Reduction of amyloid deposits1,4
AMVUTTRA uses an Enhanced Stabilization Chemistry-GalNAc conjugate designed for high metabolic stability, resulting in increased potency and prolonged duration of activity to allow infrequent dosing.1,6
GaINAc=N-acetylgalactosamine; hATTR=hereditary transthyretin-mediated; mRNA=messenger RNA; RNA=ribonucleic acid; RNAi=RNA interference; TTR=transthyretin.
Treatment with AMVUTTRA led to rapid, powerful, and sustained reduction in serum TTR7
aBars represent SEM (standard error of the mean).
aBars represent SEM (standard error of the mean).
- Serum TTR was evaluated in patients with hATTR amyloidosis with polyneuropathy treated with 25 mg of AMVUTTRA via subcutaneous injection once every 3 months1
- Similar reduction in serum TTR was observed regardless of V30M variant status, previous TTR stabilizer use, sex, age, weight, or race1,7
88% mean reduction of serum TTR
with dosing once every 3 months1,7